A Comparative study of efficacy and safety of Tapcom combination ophthalmic solution and Xalacom combination eye drops.
- Conditions
- primary open angle glaucoma or ocular hypertension
- Registration Number
- JPRN-UMIN000023862
- Lead Sponsor
- Santen Pharmaceutical Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 150
Not provided
There is risk of visual field disorder drastically progressing during the study period. Has retinal which may aggravate during the study period. Has active extraocular disease, inflammation or infection of the eye or eyelids Has corneal abnormalities or other diseases which would prohibit accurate IOP measurement by Goldmann applanation tonometer Has undergone LASIK surgery Patients who are contraindicated to beta blockers (those who with bronchial asthma or insufficiently controlled heart failure) Patients with allergy to the ingredients used in the present study Female who is pregnant, lactating, or may possibly be pregnant , wishes to become pregnant during the study period, or cannot use appropriate contraceptive method.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method IOP Change from baseline at the end of treatment
- Secondary Outcome Measures
Name Time Method